MetrioPharm Investor Relations News QII 2018


12th Annual General Meeting of MetrioPharm AG

On June 20, 2018, the 12th Annual General Meeting of MetrioPharm AG was held in Kloten (Zurich). The Management and the Board of Directors of MetrioPharm AG presented the annual report for 2017 at the beginning of the meeting. The main focus was on the discovery of the mode of action of MP1032 and the advantages of MetrioPharm's targeted therapy in contrast to the conventional treatment by immunosuppression.

MetrioPharm AG: 12th Annual General Meeting 

Also presented were the results of the Phase IIa study, which was completed in 2017 and demonstrated the very good safety profile and exploratory efficacy of MP1032. Finally, an outlook was given on the present development, especially on the current Phase II clinical trial, of which the first results (Top Line Data) are expected in the first quarter of 2019.

Following the unanimous discharge of the Board of Directors, Ekkehard Brysch and Rudolf Stäger were re-elected to the Board of Directors for a further three-year term of office. The terms of office of Markus Wenner and Dr. Werner Wolf will run for another year. Joerg Gruber was newly elected to the Board of Directors, he has been advising MetrioPharm in financial and strategic matters since 2009. Joerg Gruber has many years of experience as a venture capitalist for biotechnology and has advised on several successful company takeovers in this segment. The Board of Directors will constitute itself in the coming weeks.

Of the total share capital of CHF 19,882,000.00, divided into 99,410,000 registered shares with a par value of CHF 0.20 each, 65,221,082 shares were represented. This corresponds to 63.28 % of the issued shares. The voting results for the 12th Annual General Meeting can be found in detail on our website under MetrioPharm AG: Voting Results.

MetrioPharm in Munich, Germany

On April 16, 2018, the Investor Talks organized by the Deutsche Börse Venture Network took place in Munich. Dr. Wolfgang Brysch, CEO, and Eva Brysch, Investor Relations, represented MetrioPharm AG with a presentation to potential investors and met interested investors in the subsequent get-together.

MetrioPharm at the Swiss Biotech Day in Basel, Switzerland

The Swiss Biotech Day is an annual meeting of the Swiss biopharmaceutical industry. This year's event took place on May 3 and brought together more than 600 European life science industry executives. Dr. Wolfgang Brysch used the opportunity to network for MetrioPharm in various one-on-one meetings.

MetrioPharm in Boston, USA

The Biotechnology Innovation Organization hosted BIO 2018, one of the world's largest business partnering events. Between June 4 and 7, Dr. Wolfgang Brysch, CEO, and Felix Edler, Business Development, presented Metrio- Pharm's Phase IIa results to potential pharmaceutical partners and investors in more than 35 one-on-one meetings this year. The conference was also used to deepen existing contacts.

 MetrioPharm: Dr. Wolfgang Brysch, CEO presented Phase IIa results to potential pharmaceutical partners

MetrioPharm presents scientific data on MP1032's mode of action

At the 19th SFRRI Meeting in Lisbon, Dr. Sara Schumann, Project Manager Research and Development, presented scientific data on the mode of action of MP1032, which received very positive feedback from scientific conference participants from all over Europe.

MetrioPharm in Dublin, Ireland

On June 21, 2018, the Investor Talks organized by the Deutsche Börse Venture Network took place in Dublin. Dr. Wolfgang Brysch, CEO, and Eva Brysch, Investor Relations, presented MetrioPharm AG to potential investors and further deepened the contacts during the subsequent get-together.

MetrioPharm AG company calendar in QIII 2018

June 28-30, 2018: World Psoriasis & Psoriatic Arthritis Conference, Stockholm, Sweden
The 5th World Psoriasis & Psoriatic Arthritis Conference will take place in Stockholm at the end of June. Dr. Petra Schulz, Senior Project Manager Drug Development, will present the results of MetrioPharm' s Phase IIa study to her scientific colleagues.

July 18, 2018: Investor Talks, New York, USA
The Investor Talks organized by the Deutsche Börse Venture Network will take place in New York on July 18, 2018. MetrioPharm AG will be represented by Dr. Wolfgang Brysch, CEO, and Eva Brysch, Investor Relations, who will give a presentation to potential investors.

September 03-04, 2018: German Fall Conference, Frankfurt/Main, Germany
The annual German Fall Conference will take place in Frankfurt am Main on September 3 and 4, 2018. Exchange-listed companies present their current business figures and outlook for the following financial year to selected investors, analysts, financial journalists and other capital market participants. MetrioPharm AG will present itself as a pre-IPO company at this conference.

Should further dates be added for the third quarter, you can find out more on our website at www.metriopharm.com.

MetrioPharm Blog

Since January we are online with the MetrioPharm Blog. Here you can find detailed background information about our work. In the current entry you can find an interview with the founders of MetrioPharm AG.


Your contact:


Eva Brysch
Head of Investor Relations & Corporate Communications
Tel.: +49-(0)30-3384-395-40
E-Mail: invest@metriopharm.com


MetrioPharm AG Newsletter Download PDF